1	
2	
3	
4	Determinants of health as predictors for differential antibody
5	responses following SARS-CoV-2 primary and booster
6	vaccination in an at-risk, longitudinal cohort
7	
8	Felipe Echeverri Tribin ^{3,4†} , Erin Williams ^{1,3†} , Valeska Testamarck ⁵ , Juan Manuel Carreño ^{7,8} , Dominika
9	Bielak ⁷ , Temima Yellin ⁷ , Florian Krammer ^{7,8,9} , Michael Hoffer ^{1,5} , Suresh Pallikkuth ² , and Savita Pahwa ²
10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26	 ¹ Department of Otolaryngology, University of Miami Miller School of Medicine, Miami, Florida, 33136 USA ² Department of Microbiology and Immunology, University of Miami Miller School of Medicine, Miami, Florida, 33146, USA ³ Department of Biomedical Engineering, University of Miami, Miami, Florida, 33136, USA ⁴ University of Miami Miller School of Medicine, Miami, Florida, 33136, USA ⁵ Indiana University School of Medicine, Indianapolis, IN 46202, USA ⁶ Department of Neurological Surgery, University of Miami, Miller School of Medicine, Miami, Florida, 33136, USA ⁷ Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, 10029, USA ⁸Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai, New York, NY, USA ⁹Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
27	*Corresponding author
28	E-mail: <u>spahwa@med.miami.edu</u> (SP)
29	
30 31	[†] These authors contributed equally to this work.

It is made available under a CC-BY 4.0 International license .

2

32 Abstract

33 Post vaccine immunity following COVID-19 mRNA vaccination may be driven by extrinsic, or controllable and intrinsic, or inherent health factors. Thus, we investigated the effects of extrinsic and 34 intrinsic on the peak antibody response following COVID-19 primary vaccination and on the trajectory of 35 peak antibody magnitude and durability over time. Participants in a longitudinal cohort attended visits every 36 3 months for up to 2 years following enrollment. At baseline, participants provided information on their 37 38 demographics, recreational behaviors, and comorbid health conditions which guided our model selection process. Blood samples were collected for serum processing and spike antibody testing at each visit. Cross-39 sectional and longitudinal models (linear-mixed effects models) were generated to assess the relationship 40 41 between selected intrinsic and extrinsic health factors on peak antibody following vaccination and to determine the influence of these predictors on antibody over time. Following cross-sectional analysis, we 42 43 observed higher peak antibody titers after primary vaccination in females, those who reported recreational drug use, younger age, and prior COVID-19 history. Following booster vaccination, females and Hispanics 44 had higher peak titers after the 3rd and 4th doses, respectively. Longitudinal models demonstrated that 45 Moderna mRNA-1273 recipients, females, and those previously vaccinated had increased peak titers over 46 time. Moreover, drug users and half-dose Moderna mRNA-1273 recipients had higher peak antibody titers 47 48 over time following the first booster, while no predictive factors significantly affected post-second booster 49 antibody responses. Overall, both intrinsic and extrinsic health factors play a significant role in shaping humoral immunogenicity after initial vaccination and the first booster. The absence of predictive factors 50 51 for second booster immunogenicity suggests a more robust and consistent immune response after the second booster vaccine administration. 52

53

Key Words: "SARS-CoV-2", "primary vaccination", "booster vaccination", "humoral immunogenicity",
"breakthrough", "cross-sectional analysis", "linear mixed-effects models"

It is made available under a CC-BY 4.0 International license .

3

57 Introduction

58 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection has had rapid and widespread 59 international effects since its onset in late December 2019 (1-5). Aside from the socioeconomic burdens and turmoil generated from its spread, early access to health interventions and prophylactic measures for 60 61 the virus were limited and ineffective at controlling the spread. Instead, government-imposed lockdowns 62 and social distancing were utilized as preventative measures (4), but due to high transmissibility and 63 virulence the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) for nearly 400 coronavirus disease-19 (COVID-19) related medical products in the United States, including 64 diagnostic tests, medical devices, drugs, and vaccines (4, 6-8), and helped distribute vaccines worldwide. 65

66

Prior work has shown that post-vaccine immunity is driven by various factors, including prior SARS-CoV-2 67 68 infection, vaccine manufacturer, heterologous booster administration, time since vaccination, and the magnitude of peak antibody titers after vaccination (9-18). Furthermore, both systemic and local symptoms 69 following SARS-CoV-2 infection and vaccination have been associated with higher peak antibody 70 71 responses following primary vaccination (5). Overall, COVID-19 vaccines and boosters have been 72 demonstrated to safely curb infection and severe SARS-CoV-2 outcomes, but more work is needed to 73 understand drivers for post-vaccination heterogeneity. The effect of intrinsic health factors (IHFs) and extrinsic health factors (EHFs) on COVID-19 vaccine immunogenicity is unknown. 74 IHFs are characteristics that relate to an individual and cannot be changed or manipulated (e.g., age, biological sex, 75 76 or race), while EHFs relate to health comorbidities and behaviors (e.g., diet, smoking, or drug consumption) 77 that can be altered or controlled.

78

Accounting for IHFs and EHFs when evaluating post-vaccine immunogenicity in large populations could result in more personalized analyses from a public health approach (5). For example, prior research has shown that individuals with diabetes mellitus and obesity exhibit dampened immune responses to COVID-

It is made available under a CC-BY 4.0 International license .

4

82 19 and hepatitis B vaccines, compared to controls (19, 20). Apart from chronic disease, age, and biological 83 sex, human leukocyte antigen types have also been identified as factors that can cause heterogeneous immune reactions to vaccination due to senescence and variable cytokine production among different 84 groups (21-24). Despite these findings, the evaluation of IHFs and EHFs have yet to be determined in a 85 86 longitudinal cohort following COVID-19 vaccination. Thus, the purpose of this study is to investigate the 87 effects of IHFs and EHFs on peak antibody (Ab) titers following COVID-19 primary vaccination (PV) and booster vaccination (BV), and to investigate how these factors influence Ab magnitude and trajectory over 88 89 time.

90

91 Methods

92 Study design

93 Participants were enrolled in our Institutional Review Board (IRB) approved (#20201026), longitudinal, 94 observational SARS-CoV-2 immunity study (n=228) known as "CITY" (COVID-19 ImmuniTY study) as 95 part of the PARIS/SPARTA study (25). Recruitment for the study began in October 2020 and ended in February 2023. The study was conducted at the University of Miami Miller School of Medicine, and study 96 97 subjects participated in visits every 3 months for a total of 2 years from the time of enrollment. The primary 98 objective of the CITY study was to characterize differential antibody kinetics among SARS-CoV-2 99 uninfected and infected individuals in a high-risk, ethnically diverse cohort. The "high-risk" designation 100 for inclusion referred to hazardous occupational exposure (e.g., healthcare workers) but also to advanced age or other sociodemographic characteristics known to increase risk of SARS-CoV-2 morbidity and 101 mortality. Following written informed consent, participants provided demographic details to include social 102 103 and lifestyle habits and relevant past medical history that would preclude them to more severe SARS-CoV-2 infection-related outcomes. They also provided details regarding their past medical history to include 104 conditions like hypertension, hypercholesterolemia, previous SARS-CoV-2 infection, diabetes, and 105 106 COVID-19 vaccine manufacturer, lifestyle factors like alcohol or drug consumption, and other details such

It is made available under a CC-BY 4.0 International license .

5

107 as age, biological sex, educational level, employment status, marital status, race, ethnicity, and sexual 108 orientation. Those who suffered from SARS-CoV-2 infection with a documented positive nucleic acid 109 amplification test (NAAT+) prior to entry provided evidence details regarding their past SARS-CoV-2 110 infection associated symptoms during the baseline visit to the study team.

111

At all regularly scheduled visits, participants prospectively answered symptom questionnaires to screen for new or recent SARS-CoV-2 infection, and blood samples were collected for serum and peripheral blood mononuclear cell (PBMC) processing. Plasma was stored at -80°C and PBMCs were cryopreserved in liquid N₂ (26). All participants agreed to sample banking for future research use (Fig 1).

116

Fig 1. Overview of Experimental Methods. Classification of intrinsic and extrinsic health factors were determined by participant responses gathered during baseline questionnaires. Blood samples were collected at regular intervals, followed by processing and ELISA-mediated antibody detection with discrete titers reported from 1:100 to 1:204800. Sample analysis was achieved through cross-sectional and longitudinal analyses. Created with BioRender.com

122

123 SARS-CoV-2 ELISAs

124 SARS-CoV-2 enzyme-linked immunosorbent assays (ELISAs) were performed according to a well 125 described assay developed by the Icahn School of Medicine at Mount Sinai (27, 28). 96-well plates were collected at 4°C with wild-type Wuhan SARS-CoV-2 spike protein (2 mg/ml) solution and incubated 126 overnight. Plates were blocked with 3% non-fat milk prepared in phosphate buffered saline with 0.1% 127 Tween 20 (PBST) and incubated at room temperature for an hour. After blocking, serial dilutions of heat-128 inactivated serum samples were added to the plates and incubated for two hours at room temperature. Plates 129 were washed in triplicate with 0.1 % PBST and 50 µl of a 1:3,000 dilution of goat anti-human 130 131 immunoglobulin G-horseradish peroxide (HRP) conjugated secondary antibody was added. After an hour

It is made available under a CC-BY 4.0 International license .

6

of incubation, 100 μ l *o*-phenylenediamine dihydrochloride (SIGMAFASTTM-OPD, *Sigma Aldrich*) solution was added to each well for 10 minutes. The reaction was stopped by the addition of 50 μ l of 3 M hydrochloric acid at each well. The optical density at 490 nm (OD490) was measured using a Synergy 4 (BioTek) plate reader. The background value (OD490 = 0.15) allowed to report discrete antibody endpoint titers in the values of 1:100, 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400, 1:12800, 1:25600, 1:51200,

137 1:102400, and 1:204800. The limit of detection was set at 1:100.

138

139 Statistical analyses

- 140 For all analyses, regardless of the statistical approach, Ab titers were log₂ transformed. Intrinsic and
- 141 extrinsic factors (Table 1) were included in the cross-sectional and longitudinal analyses detailed below.

142	Table 1.	Observed	Extrinsic an	d Intrinsic	Health	Factors	Selected	as Cov	ariates.
-----	----------	----------	--------------	-------------	--------	---------	----------	--------	----------

Extrinsic Health Factors	Intrinsic Health Factors
Alcohol consumption	Age
Cardiovascular disease	Biological sex
SARS-CoV-2 infection (prior to	Educational level
vaccination)	Employment status
COVID-19 vaccine manufacturer	Marital status
Diabetes	Race (White/Black/Asian/Other)
Hypercholesterolemia	Ethnicity (Hispanic/Not Hispanic)
Hypertension	Sexual orientation
Recreational drug consumption (marijuana,	
cocaine, and/or hallucinogens)	

143

144 Cross-sectional analysis

For the cross-sectional analysis, all respondents had participated in additional visits with associated Ab titers measured within 2 weeks [\pm 5 days] following primary and booster vaccination. Cross-sectional analysis was conducted separately for post-vaccine timepoints following PV, BV1, and BV2. We included only those (n = 118) who had received their primary vaccination (i.e., two doses of Pfizer BNT162b2 or two doses of Moderna mRNA-1273) after their inclusion into the study and strictly within the two-dose

It is made available under a CC-BY 4.0 International license .

7

schedule recommended by the Centers for Disease Control and Prevention (CDC). This approach
minimized potential discrepancies in vaccination effects based on administration time.

152

The underlying assumptions for parametric tests (e.g., tests for homogeneity of variance and normality) 153 154 were conducted for Ab titers among IHF and EHF groups following each post-vaccination sub cohort of 155 interest (i.e., PV1, BV1, and BV2) prior to conducting hypothesis testing. Differences in mean Ab were 156 analyzed using parametric (one-way analysis of variance (ANOVA), Student's t-test) or non-parametric 157 (Games-Howell, Welch's t-test) tests, based on Levene's test results. Lastly, Pearson's correlation was used to examine the correlation between age and peak Ab titer. All statistical analyses were conducted via 158 Minitab (*Minitab* (21.3.1)) at a significance level of $\alpha = 0.05$, and tests for groups with sample sizes <2 159 were excluded from analysis. 160

161

162 Longitudinal analysis

The selection of covariates of interest for the longitudinal analysis was informed by the aforementioned 163 cross-sectional analysis conducted at post-primary vaccination timepoints. Preliminary analyses utilized a 164 165 range of potential predictors to evaluate their association with the response variable, $\log_2 Ab$ titers over time. From this subset, only those predictors that exhibited a significant association log₂ Ab were carried 166 167 forward as covariates of interest for the longitudinal analysis. This method ensured that the longitudinal 168 model was informed by empirically significant predictors, thus increasing the potential explanatory power and relevance of the model to the observed data. Other proven covariates of interest (5), including COVID-169 170 19 vaccine manufacturer, were included during the model generation phase as well.

171

Following the above, linear mixed-effects models were constructed to investigate the growth curve of log₂
antibody titers over time following primary vaccination (Dose 1 and 2), as well as booster vaccination (Dose
3 and Dose 4) utilizing the *nlme* and *lme4* package in R Studio. The models were designed to incorporate

It is made available under a CC-BY 4.0 International license .

8

both fixed and random effects, with the fixed effects representing the average population response and the random effects capturing subject-specific deviations. The process of model generation was initiated by constructing a maximal model, where the time since vaccination – represented as a continuous variable – was incorporated as additional polynomial terms to account for potential non-linear growth patterns. This maximal model considered the most complex growth trajectory from the outset.

180

To account for the repeated measures structure of the data, various correlation structures including compound symmetry, first-order autoregressive, and general autoregressive were compared. Model comparison was performed using the Akaike Information Criterion (AIC) and the Bayesian Information Criterion (BIC), with the model yielding the lowest values being selected as the optimal model.

185

186 **Results**

187 Cohort characteristics

188 Extrinsic health factors - summary

As seen in Table 1, among those enrolled (n = 228), the average age in the "CITY" cohort was 48.6 ± 16.56 years, with 66 (34.74%) participants classified as young, 84 (44.21%) as middle aged, and 40 (21.05%) as elderly (n = 190).

Table 2 displays a summary table for the cohort extrinsic health factors. At baseline, n = 180 (78.95%) 192 193 participants self-reported as alcohol consumers and 47 (20.61%) did not (n = 227). There were 9 (3.96%) 194 participants with a history of cardiovascular disease (CVD), 216 (95.16%) with no history of CVD, and 2 195 (0.88%) that were unsure (n = 227). Also, 9 (3.96\%) participants were diabetic, while 215 (94.72\%) were 196 not, and 3 (1.32%) were unsure (n = 227). Moreover, 16 (7.08%) participants were recreational drug users and 210 (92.92%) were not (n = 226). Among the cohort, 39 (17.18%) of the participants had 197 hypercholesterolemia, while 173 (76.21%) did not, and 14 (6.17%) were unsure (n = 227). Lastly, 37 198 199 (16.30%) participants reported hypertension, 185 (81.50%) did not, and 5 (2.20%) were unsure (n = 227).

It is made available under a CC-BY 4.0 International license .

9

200

201 Table 2. Cohort Extrinsic Health Factor Summary Table.

EXTRINSIC HEALTH FACTORS (N=228)				
Alcohol Consumption	N = 227			
No	47 (20.61%)			
Yes	180 (78.95%)			
Cardiovascular Disease	N = 227			
No	216 (95.15%)			
Yes	9 (3.96%)			
Unsure	2 (0.88%)			
COVID-19	N = 228			
No	126 (55.26%)			
Yes	99 (43.42%)			
Unsure	3 (1.32%)			
COVID-19 Primary Vaccine Manufacturer	N = 163			
Johnson & Johnson Ad26.COV2.S	8 (4.91%)			
Moderna mRNA-1273	58 (35.58%)			
Pfizer BNT162b2	97 (59.51%)			
COVID-19 Booster I Manufacturer	N = 97			
Moderna mRNA-1273 – Full	17 (17.53%)			
Moderna mRNA-1273 – Half	24 (24.74%)			
Pfizer BNT162b2	56 (57.73%)			
COVID-19 Booster II Manufacturer	N = 32			
Moderna mRNA-1273 – Full	16 (50.00%)			
Moderna mRNA-1273 – Half	1 (3.12%)			
Pfizer BNT162b2	15 (46.88%)			
Diabetes	N = 227			
No	215 (94.71%)			
Yes	9 (3.96%)			
Unsure	3 (1.32%)			
Drug Use	N = 227			
No	210 (92.92%)			
Yes	16 (7.08%)			
Hypercholesterolemia	N = 227			
No	173 (76.21%)			
Yes	39 (17.18%)			
Unsure	14 (6.17%)			
Hypertension	N = 227			
No	185 (81.50%)			
Yes	37 (16.30%)			
Unsure	5 (2.20%)			

202

Ninety-nine (43.42%) participants indicated previous SARS-CoV-2 infection at entry, while 126 (55.26%)
did not, and 3 (1.32%) were unsure (n=228). Of the 163 participants in the cohort that received PV, 8
(4.91%) received Johnson & Johnson Ad26.COV2.S, 58 (35.58%) received Moderna mRNA-1273, and 97

It is made available under a CC-BY 4.0 International license .

10

(59.51%) received Pfizer BNT162b2. Of the 97 participants that received the first booster (BV1), 17
(17.53%) received the full Moderna mRNA-1273 dose, 24 (24.74%) received the half-dose Moderna
mRNA-1273, and 56 (57.73%) received Pfizer BNT162b2. Of those 32 participants that received a second
booster (BV2), 16 (50%) received a full Moderna mRNA-1273 dose, 1 (3.12%) received the Moderna
mRNA-1273 half dose, and 15 (46.88%) received a Pfizer BNT162b2 booster. No bivalent boosters were
included in the analysis.

212

213 Intrinsic health factors - summary

Table 3 displays a summary table for the cohort intrinsic health factors. One hundred and thirty-seven

215 (60.00%) participants were female and 91 (40.00%) were male (n = 228). Furthermore, it was reported that

216 23 (10.10%) participants had an associate degree or a technical degree, 49 (21.49%) had a bachelor's

degree, 12 (5.26%) had a high school diploma or equivalent, 3 (1.32%) had less than a high school diploma,

218 111 (48.68%) had a master's degree or higher, and 29 (12.72%) had other educational levels (n = 227).

219

220 Table 3. Cohort Intrinsic Health Factor Summary Table.

INTRINSIC HEALTH FACTORS (N	= 228)
Age	N = 190
<40 – Young	66 (34.74%)
40-65 – Middle	84 (44.21%)
>65 – Elderly	40 (21.05%)
Biological Sex	N = 228
Female	137 (60.09%)
Male	91 (39.91%)
Education Level	N = 227
Associate degree or technical degree	23 (10.13%)
Bachelor's degree	49 (21.59%)
High school diploma or equivalent	12 (5.29%)
Master's degree or higher	111 (48.90%)
Other	29 (12.78%)
Employment Status	N = 226
Disabled	2 (0.88%)
Employed	188 (83.19%)
Retired	24 (10.62%)
Unemployed	12 (5.31%)
Hispanic/Non-Hispanic	N = 228

90 (39.47%)
138 (60.53%)
N = 228
19 (8.33%)
11 (4.82%)
113 (49.56%)
79 (34.65%)
6 (2.64%)
N = 228
12 (5.26%)
12 (5.26%)
21 (9.21%)
183 (80.27%)
$\mathbf{N}=228$
3 (1.32%)
15 (6.58%)
206 (90.34%)
3 (1.32%)
1 (0.44%)

221

222 Additionally, 2 (0.87%) participants were disabled, 188 (82.46%) were employed, 24 (10.54%) were 223 retired, and 12 (5.26%) were unemployed (n=226). Nineteen (8.33%) were divorced, 11 (4.82%) participated in a domestic partnership, 113 (49.57%) were married, 79 (34.65%) were single, and 6 (2.63%) 224 225 were widowed (n = 228). In addition, 12 (5.26%) participants identified as Asian, 12 (5.26%) as African 226 American, 183 (80.27%) as White, and 21 (9.21%) as part of another race (n = 228). Ninety (39.47%) participants identified as Hispanic, and 138 (60.53%) participants identified as non-Hispanic. Lastly, 3 227 228 (1.32%) participants identified as bisexual, 15 (6.58%) as gay, 206 (90.35%) as heterosexual, 3 (1.32%) as lesbian, and 1 (0.43%) as another sexual orientation (n = 228). 229

230

231 **Primary vaccination**

Overall, 148 participants were included in the PV sub-cohort, with an average peak titer of 13.29 ± 1.67

following vaccination. Table 4 details all significant differences observed across extrinsic and intrinsic

health factor covariates in the PV sub-cohort or that had significance in the BV1 and BV2 sub-cohorts.

235 Other measures examined for the purpose of this analysis are documented in S1 Table.

236

It is made available under a CC-BY 4.0 International license .

12

239

240

241

237 Table 4. Mean Log₂ Ab Titers in Primary Vaccination Sub-Cohort with Varying Extrinsic and

238 Intrinsic Health Factors.

COVID-19	Ν	Mean $\log_2 Ab (\pm SD)$	р
Primary Vaccination $(n = 148)$		ŧ	
No	94 (63.15%)	12.62 (± 1.59)	< 0.005 *
Yes	54 (36.49%)	14.39 (± 1.15)	
Drug Use			
Primary Vaccination $(n = 148)$			
No	139 (93.92%)	$13.20 (\pm 1.70)$	0.050 *
Yes	9 (6.08%)	14.31 (± 0.70)	
IN	TRINSIC HF ALTH	FACTORS	
Ασρ		11101010	
Primary Vaccination $(n = 149)$			
<40 - Young	55 (36.91%)	$13.57 (\pm 1.41)$	0.026 *
40-65 – Middle	60 (40.27%)	$13.36 (\pm 1.75)$	01020
>65 – Elderly	34 (22.82%)	12.61 (± 1.78)	
Biological Ser			
Primary Vaccination $(n = 149)$		#	
Female	86 (57 72%)	$13.56 (\pm 1.46)$	0.015 *
Male	63 (42.28%)	$12.87 (\pm 1.86)$	00010
Employment Status			
Employment Status Primary Vaccination $(n - 1.48)$		+++	
Employed	125 (84 46%)	13 36 (+ 1 63)	0 037 *
Retired	17 (11 49%)	$12.35 (\pm 1.05)$	0.057
Unemployed	6 (4.05%)	$13.98 (\pm 0.82)$	
Hispanic/Non-Hispanic			
Primary Vaccination $(n = 149)$			
Hispanic	57 (38.26%)	$13.57 (\pm 1.77)$	0.079
Non-Hispanic	92 (61.74%)	$13.08 (\pm 1.58)$	5.079
Significant differences in peak	Ab were observed	between individuals with (14	4.39 ± 1.15)
without (12.62 ± 1.59) a previo	us COVID-19 infe	ction drug users (14.31 ± 0.5)	70) and non.

It is made available under a CC-BY 4.0 International license .

13

242	1.63) and retired (12.35 \pm 1.96) participants, and males (12.87 \pm 1.86) and females (13.56 \pm 1.46)
243	(T = -7.76; p < 0.005, T = -1.95; p = 0.050, F = 3.73; p = 0.026, F = 3.37; p = 0.037, T = 2.47;
244	p = 0.015, respectively).
245	[‡] : Levene's test found a statistically significant difference in the variances between COVID-19-
246	vaccinated and unvaccinated individuals (F $(1,147) = 4.92$; p = 0.028).
247	#: Levene's test found a statistically significant difference in the variances between female and
248	male participants (F $(1,148) = -4.68$; p = 0.032) after PV.
249	##: Levene's test found a statistically significant difference in the variances between employed,
250	unemployed, and retired participants (F $(2,147) = 4.41$; p = 0.015) after BV1.

251

252 Extrinsic health factors

253 Five (3.42%) individuals included in the PV sub-cohort had CVD. while the remaining 141 (96.58%) did not. The mean $\log_2 Ab$ of participants with CVD (12.84 ± 3.11) and without CVD (13.29 ± 1.59) were not 254 statistically different (T = 0.59; p = 0.555). Four who received PV (2.72%) had diabetes and 143 (97.28%) 255 256 did not. The mean $\log_2 Ab$ of participants with diabetes (12.89 ± 2.87) and participants without diabetes (13.31 ± 1.61) were not statistically different (T = 0.50; p = 0.619). Twenty-seven (19.42%) had 257 hypercholesterolemia while 112 (80.58%) did not. The mean log₂ Ab of participants with 258 hypercholesterolemia (13.01 ± 1.96) and without hypercholesterolemia (13.31 ± 1.60) were not statistically 259 different (T = 0.83; p = 0.405). Furthermore, 22 (15.07%) had hypertension and 124 (84.93%) did not have 260 261 hypertension. The variances of $\log_2 Ab$ between participants with hypertension and participants without hypertension were statistically different, (F(1,145) = 8.15; p = 0.005) and indicated that individuals without 262 hypertension had lower and more homogenous Ab response after PV. However, the mean log₂ Ab of 263 264 participants with hypertension (12.69 \pm 2.36) and participants without hypertension (13.34 \pm 1.50) were not statistically different (T = 1.24; p = 0.225). 265

266

It is made available under a CC-BY 4.0 International license.

14

267 Fifty-four (36.49%) of those that received PV reported prior SARS-CoV-2 infection at study entry and 94 (63.51%) did not. The variances of log₂ Ab between participants with a history of COVID-19 and no history 268 of COVID-19 were statistically different (F(1,147) = 4.92; p = 0.028), as were the peak responses among 269 270 participants with a COVID-19 history (14.39 \pm 1.15) and no history of COVID-19 (12.62 \pm 1.59) (T = -271 7.76; p < 0.005). Furthermore, 149 participants received PV, where 54 (36.24%) received a Moderna vaccine and 95 received a Pfizer BNT162b2. The mean log₂ Ab of participants with the Moderna mRNA-272 273 1273 vaccine (13.50 \pm 1.71) and the Pfizer BNT162b2 vaccine (13.14 \pm 1.64) were not statistically different, as shown in Fig 2 (T = 1.26; p = 0.211). Of the 148 participants who received PV, 119 (80.41%) 274 were alcohol consumers and 29 (19.59%) were not alcohol consumers. The mean log₂ Ab of alcohol 275 276 consumers (13.39 \pm 1.58) and non-alcohol consumers (12.75 \pm 1.97) were not significantly different (T = -277 1.87; p = 0.063) after PV. Moreover, of the 148 participants that received PV, 9 (6.08%) were recreational 278 drug users and 139 (93.92%) were not. The mean \log_2 Ab of recreational drug users (14.31 ± 0.70) and non-users (13.20 ± 1.70) were statistically different (T = -1.95; p = 0.050) after PV. 279

280

Fig 2. Post-Primary Vaccination Mean Log₂ Ab Across COVID Vaccine Groups. There was no significant difference (T=1.26, p=0.211) between mean $\log_2 Ab$ between participants who received Moderna mRNA-1273 (13.50 ± 1.71) or Pfizer BNT162b2 vaccines (13.14 ± 1.64) for their primary vaccination after 2 weeks of vaccination onset.

285

286 Intrinsic health factors

Of the 149 participants that received PV, 55 (36.91%) of them were young, 60 (40.27%) were middle aged, and 34 (22.82%) were elderly. The mean $\log_2 Ab$ of low age participants (13.57 ± 1.41; Tukey = A) was statistically different (*Fig 3*) than elderly participants (12.61 ± 1.78 ; *Tukey* = B), but not middle-aged participants (13.36 ± 1.75 ; *Tukey* = A , B) after PV (*F* = 3.73 ; *p* = 0.026). Pearson correlation demonstrated a negative correlation between age and $\log_2 Ab$ after PV (*r* = -0.206; *p* = 0.012). Additionally, 86 (57.72%)

It is made available under a CC-BY 4.0 International license .

15

292	participants were female and 63 (42.28%) were male. The variances of the $\log_2 Ab$ between female and
293	male participants were significantly different ($F(1,148) = -4.68$; $p = 0.032$) after PV. Furthermore, male
294	participants exhibited a lower (12.87 \pm 12.87) was statistically lower ($T = 2.47$; $p = 0.015$) than that of
295	female (13.56 \pm 1.46) participants after PV (<i>Fig 4</i>).

296

Fig 3. Post-Primary Vaccination Means Log₂ Ab Across Age Groups. The mean log2 Ab of low age participants (13.57 ± 1.41; Tukey = A) was statistically different than elderly participants (12.61 ± 1.78; Tukey = B), but not middle-aged participants (13.36 ± 1.75; Tukey = A, B) after primary vaccination (F =3.73; p = 0.026).

301

Fig 4. Post-Primary Vaccination Mean Log₂ Ab Across Biological Sex Groups. The mean \log_2 Ab in male participants (12.87 ± 12.87) was statistically lower (T=2.47, p=0.015) than that of female (13.56 ± 1.46) participants after primary vaccination

305

306 Furthermore, of the 149 participants that received PV, 12 (8.05%) reached an education level of an associate 307 degree or technical degree, 30 (20.13%) held a bachelor's degree, 9 (6.04%) a high school diploma, 75 (50.34%) a master's degree or higher, and 23 (15.44%) reported reaching an unlisted level. Peak titers were 308 not associated with differences between any group (F = 1.87); (p = 0.120), including those with an associate 309 310 degree or technical degree (13.56 \pm 1.44; *Tukey* = A), a bachelor's degree (13.68 \pm 1.69; *Tukey* = A), a high school diploma (13.98 \pm 1.58; Tukey = A), a master's degree or higher (13.16 \pm 1.64; Tukey = A), 311 and other educational levels (12.64 \pm 1.76; *Tukey* = A). One-hundred and twenty-five (84.46%) were 312 employed, 17 (11.49%) were retired, and 6 (4.05%) were unemployed. The mean \log_2 Ab of employed 313 314 $(13.36 \pm 1.63, Tukey = A)$, retired $(12.35 \pm 1.96; Tukey = A)$, and unemployed $(13.98 \pm 0.82, Tukey = A)$ participants were statistically different (F = 3.37; p = 0.037) after PV, though the authors speculate that 315 316 this finding is due to a strong correlation between age and the retired group.

317

It is made available under a CC-BY 4.0 International license .

16

318 Twelve (8.05%) participants were divorced, 7 (4.70%) participated in a domestic partnership, 81 (54.36%) 319 were married, 47 (31.54%) were single, and 2 (1.35%) were widowed. The post PV Ab between divorced $(13.81 \pm 1.24, Tukey = A)$, domestic partnership $(13.07 \pm 1.51, Tukey = A)$, married $(13.04 \pm 1.82, Tukey = A)$ 320 321 = A), and single $(13.54 \pm 1.49, Tukev = A)$ participants were not statistically different (F = 1.36; p = 0.257) 322 after PV. Only 2 (1.34%) identified as bisexual, 10 (6.71%) identified as gay, 134 (89.94%) identified as heterosexual, 2 identified as lesbian (1.34%), and 1 (0.67%) identified as another sexual orientation. 323 324 Furthermore, the mean $\log_2 Ab$ between gay (13.34 ± 0.45) and heterosexual (13.24 ± 0.15) participants were not significantly different (T = 0.19; p = 0.853) after PV. 325 326

Also, of the 149 participants that received PV, 9 (6.04%) were Asian, 6 (4.03%) were African American, 14 (9.40%) identified under another race, and 120 (80.54%) were White, though the mean peak response (13.09 ± 1.88, *Tukey* = A; 13.98 ± 0.82, *Tukey* = A; 13.43 ± 1.37, *Tukey* = A; 13.23 ± 1.72, *Tukey* = A; respectively) were not statistically different (F = 0.46; p = 0.712) after PV. Moreover 57 (38.26%) participants identified as Hispanic, and 92 (61.74%) identified as non-Hispanic. The mean log₂ Ab between Hispanic (13.57 ± 1.77) and non-Hispanic (13.08 ± 1.58) participants were not statistically different (T =1.77; p = 0.079) after PV.

334

Longitudinal analysis following primary vaccination

A linear mixed-effects model (Fig 5) was employed to investigate the fixed effects of days since full vaccination (including linear, quadratic, and cubic time), COVID-19 vaccine manufacturer, COVID-19 status, and biological sex on the log-transformed titer levels (antibody), while accounting for random effects associated with each study participant. The fixed effects of linear, cubic, and quadratic time revealed that days since full vaccination (i.e., >14 days following the 2nd dose) and its second and third powers were negatively associated with log₂ antibody titers (*estimate* = -4.653e^-03; *F*(1,524) = 96.889; *p* = <0.001, *estimate* = -2.208e^-04; F(1,524) = 118.393; *p* <0.001, and *estimate* = 9.467e^-07; *F*(1,24) = 44.654; *p* <

It is made available under a CC-BY 4.0 International license .

17

343 0.001, respectively). Participants who had been vaccinated with Pfizer BNT162b2 had a lower antibody 344 response over time compared to those who received the Moderna mRNA-1273 vaccine (*estimate* = -9884e^-345 01; F(1,108) = 36.900; p < 0.001).

346

Fig 5. Linear Mixed-Effects Model for Investigation of Fixed Effects of Days Since Full Vaccination,
Primary Covid-19 Vaccine Manufacturer, Covid-19 Status, And Biological Sex. Moderna mRNA-1273
recipients exhibited higher peak titers as well as more durable antibody responses when compared to Pfizer
BNT162b2, as did study participants who were previously COVID-19 positive prior to vaccine recipient.
Male participants, on average, demonstrated lower Ab responses when compared to female participants.
Additionally, COVID-19 positive participants had higher antibody levels compared to COVID-19 negative

Additionally, COVID-19 positive participants had higher antibody levels compared to COVID-19 negative

individuals (*estimate* = 1.464; F(1,108) = 64.917; p < 0.001), consistent with well-described trends for

hybrid immunity (29). The analysis also suggested a difference in antibody levels based on biological sex,

with males having lower levels compared to females (*estimate* = $-3.759e^{01}$; F(1,108) = 4.856; p = 0.030).

357 No other variable was found to significantly influence log₂ antibody titers over time (S2 Table).

358

359 Booster vaccine I

Following Booster Vaccine I (BV1), 148 participants averaged a mean peak titer of 17.74 ± 1.14 . Table 5 details significant differences observed across all extrinsic and intrinsic health factors in the BV1 sub-cohort or that were noted to be significant in the PV and BV2 sub-cohorts. Other measures are documented in S3 Table.

364

Table 5. Mean log₂ Ab titers in first booster vaccination sub-cohort with varying extrinsic and

366 intrinsic health factors.

BOOSTER VACCINATION I EXTRINSIC HEALTH FACTORS – BOOSTER VACCINATION I

It is made available under a CC-BY 4.0 International license .

COVID-19	Ν	Mean $\log_2 Ab (\pm SD)$	р
Booster Vaccination I ($n = 98$)			
No	68 (69.39%)	14.70 (± 1.20)	0.649
Yes	30 (30.61%)	14.81 (± 1.02)	
Drug Use			
Booster Vaccination I (n=97)			
No	93 (95.88%)	$14.74 (\pm 1.15)$	0.794
Yes	4 (4.12%)	$14.89 (\pm 0.96)$	
	. (,.)		
INTRINSIC HEALT	H FACTORS – VA	CCINATED PARTICIPANTS	7
Age			,
Booster Vaccination I (n=98)			
<40 - Young	24 (24,49%)	$15.06 (\pm 0.97)$	0.277
40-65 – Middle	43 (43.88%)	$14.62 (\pm 0.96)$	
>65 - Elderly	31 (31.63%)	$14.64(\pm 1.44)$	
	· · ·		
Biological Sex			
Booster Vaccination I (n=98)			
Female	50 (51.02%)	14.96 (± 1.22)	0.043 *
Male	48 (48.98%)	14.50 (± 1.01)	
Employment Status			
$\frac{1}{2} Employment Status}{Pooster Vaccination I (n=07)}$			
$\frac{1}{1} \frac{1}{1} \frac{1}$	78 (80 /10/)	$14.82 (\pm 0.04)$	0.541
Ratirad	10(00.4170)	$14.82 (\pm 0.94)$ $14.29 (\pm 1.91)$	0.541
Unamployed	5(516%)	$14.29 (\pm 1.91)$ 15 04 (± 0.89)	
Onemployed	5 (5.1070)	15.04 (± 0.07)	
Hispanic/Non-Hispanic			
Booster Vaccination $I(n=98)$			
Hispanic	34 (34.69%)	$14.97 (\pm 0.98)$	0.144
Non-Hispanic	64 (65.31%)	14.61 (± 1.21)	
Non-Hispanic	64 (65.31%)	$14.61 (\pm 1.21)$ between males (14.50 ± 1.01) and fema

368

367

 (14.96 ± 1.22) following BV1 (T = -2.05; p = 0.043).

369

Extrinsic health factors 370

Of the 95 participants that received BV1, 3 (3.16%) had CVD and 92 (96.84%) did not have CVD. 371

372 Additionally, the mean \log_2 Ab of participants with CVD (14.64 ± 1.00) and participants without CVD

 (14.75 ± 1.15) did not significantly vary (T = 0.16; p = 0.872) after BV1. Three (3.12%) had diabetes and 373

93 (96.88%) did not, but diabetic (13.98 \pm 1.53) and non-diabetic (14.77 \pm 1.14) participants did not have 374

It is made available under a CC-BY 4.0 International license .

19

375	observable differences ($T = 1.19$; $p = 0.239$) in peak titers. Of the 89 participants that received BV1, 23
376	(25.84%) had hypercholesterolemia and 66 (74.16%) did not. Eighteen (18.95%) participants had
377	hypertension and 77 (81.05%) did not. Among participants with hypercholesterolemia (14.73 \pm 0.95) or
378	without (14.81 \pm 1.25), and hypertension (14.81 \pm 0.22) or without (14.75 \pm 1.12), we did not observe
379	differences in peak BV1 response ($T = 0.28$; $p = 0.781$, $T = -0.21$; $p = 0.836$).

380

381 Thirty (30.61%) participants who received BV1 were previously infected with SARS-CoV-2 and 68 (69.39%) were not. Furthermore, the mean $\log_2 Ab$ of participants with a COVID-19 history (14.81 ± 1.02) 382 and no history (14.70 \pm 1.20) were not statistically different (T = -0.46; p = 0.649) after BV1. In the BV1 383 sub-cohort, 17 (17.52%) received a full-dose Moderna mRNA-1273 vaccine, while 24 (24.74%) received 384 a half-dose Moderna mRNA-1273 vaccine, and 56 (56.74%) received a Pfizer BNT162b2 vaccine, but the 385 386 mean $\log_2 Ab$ in participants with full-dose Moderna mRNA-1273 (14.82 ± 1.55; Tukey = A), half-dose 387 Moderna mRNA-1273 (15.14 \pm 0.78; *Tukey* = A), and Pfizer BNT162b2 (14.54 \pm 1.10 log₂ Ab; *Tukey* = A) did not have significantly distinct peak responses (F = 2.51; p = 0.087). 388

389

Interestingly, the Pfizer BNT162b2 BV1 group exhibited a very homogeneous peak response following vaccination (14.54; SE = 0.02) while ultimately it was not statistically different from the other groups. Of the 97 participants that received BV1, 74 (76.29%) were alcohol consumers and 23 (23.71%) were not. The peak response of alcohol consumers (14.85 ± 1.01) and non-consumers (14.43 ± 1.48) were not significantly different (T = -1.55; p = 0.124). Four (4.12%) participants were recreational drug users and 93 (95.88%) were not, and the peak response was not significantly different (T = -0.26; p = 0.794) between drug users (14.89 ± 0.96) and non-users (14.74 ± 1.15).

397

398 Intrinsic health factors

It is made available under a CC-BY 4.0 International license .

20

Twenty-four (24.49%) young participants were in the BV1 sub-cohort, while 43 (43.88%) were of middle age, and 34 (34.69%) were elderly. The peak response among different age groups was not significantly different (F = 1.30; p = 0.277), including young (15.06 ± 0.97 ; *Tukey* = A), middle-aged (14.62 ± 0.96 , *Tukey* = A), and elderly participants (14.46 ± 1.44 ; *Tukey* = A). Of the 98 participants that received BV1, 50 (51.02%) were female and 48 (49.98%) were male, and a significantly lower peak response (T = -2.05; p = 0.043) was observed in males (14.50 ± 1.01) in comparison to females (14.96 ± 1.22).

405

Of the 98 participants that received BV1, 10 (10.20%) obtained an associate degree or technical degree, 21 406 (21.43%) a bachelor's degree, 2 (2.04%) a high school diploma, 48 (48.98%) a master's degree or higher, 407 408 and 17 (17.35%) reported an unlisted level. The mean $\log_2 Ab$ between participants with an associate degree 409 or technical degree (14.84 \pm 1.62; *Tukey* = A), a bachelor's degree (14.64 \pm 1.38; *Tukey* = A), a master's 410 degree or higher $(14.81 \pm 0.91; Tukey = A)$, and other educational levels $(14.64 \pm 1.23; Tukey = A)$ were not statistically different (F = 0.17; p = 0.916). Seventy-eight participants (80.41%) were employed, 14 411 (14.43%) were retired, and 5 (5.16%) were unemployed. We observed that the variances of $\log_2 Ab$ between 412 employed, retired and unemployed participants were statistically different (F(2,147) = 4.41; p = 0.015) 413 414 after BV1, though the peak responses were not significantly different (F = 0.66; p = 0.541) between these 415 groups $(14.82 \pm 0.94, Games-Howell = A; 14.29 \pm 1.91, Games-Howell = A; 15.04 \pm 0.89; Games-Howell$ = A; respectively). 416

417

In the BV1 sub-cohort, 8 (8.16%) participants were divorced, 4 (4.08%) participated in a domestic partnership, 61 (62.24%) were married, 22 (22.45%) were single, and 3 (3.07%) were widowed. The mean log₂ Ab between divorced (15.02 \pm 1.06; *Tukey* = A), domestic partnership (14.39 \pm 0.96; *Tukey* = A), married (14.68 \pm 1.22; *Tukey* = A), single (14.83 \pm 1.01; *Tukey* = A), and widowed (14.98 \pm 1.16; *Tukey* = A) participants were not statistically different (*F* = 0.31; *p* = 0.869) after BV1. One (1.02%) identified as bisexual, 6 (6.12%) identified as gay, 90 (91.84%) identified as heterosexual, and 1 identified as lesbian

It is made available under a CC-BY 4.0 International license .

21

424 (1.02%), but the mean \log_2 Ab between gay (14.31 ± 0.82) and heterosexual (14.74 ± 1.15) participants 425 were not significantly different (T = -0.90; p=0.368) following BV1.

426

Finally, of the 98 participants that received BV1 8 (8.16%) were Asian, 3 (3.06%) were African American, 5 (5.11%) identified under another race, and 82 (83.67%) were White. The peak responses between participants among different races were not statistically different (F = 0.41; p = 0.747), including Asian (14.77 ± 0.84; *Tukey* = A), African American (15.32 ± 0.58; *Tukey* = A), Other (15.04 ± 0.55; *Tukey* = A), and White (14.69 ± 1.21; *Tukey* = A). Of the 98 participants that received BV1, 34 (34.69%) identified as Hispanic, and 64 (65.31%) identified as non-Hispanic. The mean log₂ Ab between Hispanic (14.97 ± 0.98) and non-Hispanic (14.61 ± 1.21) participants were not statistically different (T = 1.47; p = 0.144) after BV1.

435 Longitudinal analysis following booster vaccination I

Linear mixed effects models were generated to examine the effect of IHFs and EHFs on log₂ antibody titers 436 over time following BV1 (Fig 6). Overall, we found that the quadratic (*estimate* = -6.657e-04; F(1, 72) =437 4.007; p = 0.049) and cubic (estimate = 1.827e-06; F(1, 72) = 10.142; p = 0.002) terms for days elapsed 438 439 since the first booster were observed to be a significant predictor of log₂ antibody titers over time, elucidating a non-linear decay pattern following BV1. Curiously, this analysis also revealed that drug use 440 positively impacted \log_2 antibody titers, (estimate = 2.527e+00; F(1, 24) = 8.917; p = .006). Following 441 post-hoc testing, booster type (i.e., Pfizer BNT162b2 vs. Moderna mRNA-1273 (full dose) vs. Moderna 442 443 mRNA-1273 (half dose) was found to significantly affect the trajectory of \log_2 antibody titers, (estimate = 3.997416e-01; F(2, 24) = 4.755; p = .018), with those who received a half-dose of the Moderna mRNA-444 1273 booster displaying increased log₂ antibody titers boasting significantly higher titers than who received 445 446 the Pfizer BNT162b2 booster.

447

It is made available under a CC-BY 4.0 International license .

22

448	Fig 6. Linear mixed-effects model for investigation of IHFs and EHFs on log ₂ antibody titers over
449	time following BV1. The quadratic and cubic terms for days indicate a nonlinear decay of titers over
450	time. Additionally, the model indicated that drug use and vaccination with the half-dose Moderna mRNA-
451	1273 vaccine positively impacted titers. Other factors did not contribute significantly to titers over time.
452	
453	Notably, factors such as ethnicity, gender, age at entry, race, and the linear term for the number of days
454	since the first boost did not significantly contribute to the variation in \log_2 antibody titers, all $p > .05$ (S4
455	Table).
456	
457	Booster vaccine II
458	In the cohort, 24 participants received BV2 and averaged 15.06 ± 1.61 Ab following vaccination. Table 6 details the
459	extrinsic and intrinsic health factors that observed a significant difference within groups in the BV2 cohort or that had
460	significance in the PV and BV1 sub-cohorts. Other measures are documented in S5 Table.
461	

462 Table 6. Mean log₂ Ab titers in second booster vaccination sub-cohort with varying extrinsic and
463 intrinsic health factors.

BC	DOSTER VACCIN	NATION II		
EX	TRINSIC HEALTH	I FACTORS		
COVID-19	Ν	Mean $\log_2 Ab (\pm SD)$	р	
Booster Vaccination II $(n = 24)$				
No	21 (87.50%)	15.07 (± 1.69)	0.908	
Yes	3 (12.50%)	14.98 (± 1.16)		
Drug Use				
Booster Vaccination II $(n=23)$				
No	21 (91.30%)	15.03 (± 1.65)		
Yes	2 (8.70%)	16.14 (± 0.71)		
IN	TRINSIC HEALTH	FACTORS		
Age				
Booster Vaccination II $(n = 24)$				
<40-Young			0.573	

It is made available under a CC-BY 4.0 International license .

23

40-65 - Middle	7 (29 17%)	$1536(\pm 150)$	
>65 Elderhy	17(70.830/)	$14.04 (\pm 1.60)$	
>0J - Elderly	17 (70.8370)	$14.94(\pm 1.09)$	
Biological Sex			
Booster Vaccination II (n=24)			
Female	10 (41.67%)	15.04 (± 1.78)	0.967
Male	14 (58.33%)	15.07 (± 0.42)	
Employment Status			
Booster Vaccination II (n=24)			
Employed	14 (58.33%)	15.29 (± 1.50)	0.556
Retired	9 (37.50%)	$14.87 (\pm 1.86)$	
Unemployed	1 (4.17%)		
Hispanic/Non-Hispanic			
Booster Vaccination II $(n=24)$			
Hispanic	4 (16.67%)	$16.64 (\pm 0.82)$	0.028 *
Non-Hispanic	20 (83.33%)	14.74 (± 1.55)	

464

465

 (14.74 ± 1.55) participants following BV2 (T = 2.35; p = 0.028).

466

467 Extrinsic health factors

468 In the BV2 sub-cohort 2 (9.09%) had CVD and 20 (90.91%) did not have CVD, 2 (8.70%) had diabetes

and 21 (91.30%) did not have diabetes, and 10 (47.62%) had hypercholesterolemia and 11 (52.38%) did

470 not have hypercholesterolemia. The peak response of participants with hypercholesterolemia (15.54 ± 0.99)

and without (14.92 ± 2.01) were not statistically different (T = -0.89; p = 0.383) after BV2. Five (21.74%)

had hypertension and 18 (78.26%) did not, but the peak responses between those with hypertension (15.84

473 ± 0.37) and without (14.92 ± 1.74) were not statistically different (T = -1.13; p = 0.270).

474

475 Three (12.50%) participants from the BV2 sub-cohort were infected with SARS-CoV-2 prior to enrollment

476 and 21 (87.50%) were not. The mean $\log_2 Ab$ of participants with prior SARS-CoV-2 infection (14.98 ±

477 1.16) and no prior infection (15.07 ± 1.69) were not statistically significant (T = 0.13; p = 0.908). Thirteen

It is made available under a CC-BY 4.0 International license .

24

478 (54.17%) received a full-dose Moderna mRNA-1273 vaccine, while 11 (45.83%) received a Pfizer 479 BNT162b2 vaccine, but the peak responses between Moderna mRNA-1273 (15.41 ± 1.74) and Pfizer 480 BNT162b2-vaccinated (14.64 ± 1.41) participants were not significantly different (T = 1.17; p = 0.253). Of 481 the 23 participants that received BV2, 17 (73.91%) were alcohol consumers and 6 (26.09%) were not. The 482 mean log₂ Ab of alcohol consumers (14.94 ± 1.21) and non-alcohol consumers (15.64 ± 2.53) were not 483 significantly different (T = 0.91; p = 0.371) after BV2. Two (8.70%) participants were drug users and 21 484 (91.30%) were not.

485

486 Intrinsic health factors

Of the 24 participants that received BV2, 7 (29.17%) were middle aged and 17 (70.83%) were elderly. The peak response of middle-aged participants (15.36 ± 1.50) and elderly participants (14.96 ± 1.69) was not significantly different (T = -0.57; p = 0.573). Ten (41.67%) participants were female and 14 (58.33%) were male, and the peak response in male (15.07 ± 0.42) and female (15.04 ± 1.78) participants was not statistically different (T = -0.04; p = 0.967) after BV2.

492

Two (8.33%) participants had an associate degree or technical degree, 5 (20.83%) had a bachelor's degree, 13 (54.17%) had a master's degree or higher, and 4 (16.67%) had an unlisted degree. The peak responses among participants in this group were not statistically different (F = 0.64, p = 0.539), including those with a bachelor's degree (14.44 ± 2.39; *Tukey* = A), a master's degree or higher (14.03 ± 1.26; *Tukey* = A), and other educational levels (15.64 ± 1.41; *Tukey*=A). Of the 24 participants that received BV2, 14 (58.33%) were employed, 9 (37.50%) were retired, and 1 (4.17%) was unemployed. The Ab of employed (15.29 ± 1.50) and retired (14.87 ± 1.86) participants were not statistically different (T = 0.60; p = 0.556) after BV2.

501 In the BV2 cohort, 3 (12.50%) participants were divorced, 1 (4.17%) participated in a domestic partnership,

502 16(66.67%) were married, 2(8.33%) were single, and 2(8.33%) were widowed. The mean $\log_2 Ab$ between

It is made available under a CC-BY 4.0 International license .

25

503	divorced (15.98 \pm 0.58) and married (14.77 \pm 1.75) participants were not statistically different (T = 1.61; p
504	= 0.261). Two (8.33%) identified as gay and 22 (91.67%) identified as heterosexual.

505

Four (16.67%) identified as Hispanic, and 20 (83.33%) identified as non-Hispanic. The peak response between Hispanic (16.64 \pm 0.82) and non-Hispanic (14.74 \pm 1.55) participants were statistically different (*T* = 2.35; *p* = 0.028) after BV2. Of the 24 participants that received BV2, 2 (8.33%) were Asian, 2 (8.33%) were African American, 2 (8.33%) identified under another race, and 18 (75.01%) were White.

510

511 Longitudinal analysis following booster vaccination II

512 Lastly, linear mixed effects models were used to generate a growth curve of the log₂ Ab response following 513 BV2. Again, the quadratic term for the number of days since the 2nd booster emerged as a significant predictor of log₂ antibody titers, (estimate = -6.628^e-05; F(1, 104) = 7.916; p = .006), suggestive of a non-514 linear decay pattern following vaccination. No other covariate of interest was found to significantly affect 515 the trajectory of Ab over time, including linear or cubic time, gender, booster type, or drug use (S6 Table). 516 517 Overall, these results suggest that a 4th dose of an mRNA COVID-19 vaccine provide an additive effect on 518 the immune response, dampening the role of underlying IHF and EHFs that may influence the post-vaccine 519 immune response.

520

521 **Discussion**

In this work, we sought to evaluate the effects of intrinsic and extrinsic health factors on the peak antibody response as well as characterize antibody trajectory over time following COVID-19 mRNA primary vaccination and booster vaccination. Through cross-sectional analysis, we found that EHFs influenced Ab production after primary vaccination. Participants that reported recreational drug use, including marijuana, cocaine, and amphetamines had marginally higher log₂ Ab compared to non-users after PV, but not BV1 or

It is made available under a CC-BY 4.0 International license .

26

527 BV2. Previous work has shown that recreational drug use is immunomodulatory, increasing the 528 susceptibility to infectious diseases and microbes while impairing antibody production following 529 vaccination (30-33). Our findings support the opposite, though this warrants further investigation given the 530 small sample size of drug users in our cohort. This was further substantiated in linear mixed-effects models, 531 which demonstrated that participants with reported drug use had higher titers over time only after BV1.

532

533 Our cross-sectional analyses were inherently limited in their ability to control for all other variables that 534 may influence humoral responses and were utilized in the context of this work to capture only the peak 535 antibody response. Further, unlike mixed effects models, a cross-sectional approach does not permit the assessment of the impact of individual covariates while controlling for the effect of time elapsed since 536 vaccination. We also found that individuals without hypertension had a lower and more homogeneous Ab 537 538 response following PV, but not BV1 or BV2, which may be attributed to previously reported changes in T 539 cell immunometabolism (i.e., aberrant T cell activation, differentiation, and proliferation) (34-38). Studies 540 evaluating the effect of hypertension on antibody titers have provided variable results, with some supporting hypertension as a factor driving vaccine immunogenicity (37, 38), and others refuting it (39). We also 541 542 observed significantly higher mean peak log₂ Ab in participants with previous SARS-CoV-2 infection compared to those without a history after only PV, consistent with previous findings (5, 40, 41). Lastly, no 543 544 significant difference in the peak log₂ Ab was found between participants that received Moderna mRNA-1273 and Pfizer BNT162b2 vaccines after vaccination, although this was not the case over time. 545

546

Young (low age) individuals had higher peak Ab compared to elderly participants, but not middle-aged participants only after PV, which may be attributed to age-related defects in lymphocytes like mature lymphocyte senescence or decreased production and proliferation of lymphocytes and their associated biomarkers (42-46). Furthermore, we observed significantly lower Ab in retired participants following PV, which likely corresponds to the advanced age of those participants. Also, we found that non-Hispanic participants had lower Ab than Hispanic after BV2, but our sample size is limited and therefore may be

It is made available under a CC-BY 4.0 International license .

27

limited in generalizability. Lastly, we found that females had significantly higher Ab following PV and BV1, but not BV2. Differences in immune responses based on biological sex may be linked to phylogenetic preservation and subsequent reproductive success associated with more robust humoral immune reaction in females (47). Accordingly, the decreased peak Ab responses we observed in males is supported by previously documented sex-related humoral and cellular-mediated differences (40, 47-49).

558

559 The overall findings from the cross-sectional approach indicate, at least in part, the role of EHFs and IHFs in generating differential humoral immunes response following COVID-19 vaccination. Notably, these 560 analyses did not control for other variables, which increases the likelihood of introducing confounding 561 562 factors in the analysis. Thus, cross-sectional analyses should be considered useful in identifying differences in immune response following vaccination but are perhaps limited in evaluating how these change over 563 564 time. Additionally, controlling for other factors can help determine more robust relationships between Ab 565 and IHFs/EHFs. Because the immune system follows a dynamic response following activation both through 566 time and due to inter-individual differences, adopting models that account for this and can control for these differences may be used to corroborate cross-sectional analysis. Thus, distinct linear mixed-effects models 567 568 were used to investigate the factors influencing the log-transformed titer levels following primary and booster vaccination. The number of days elapsed since primary vaccination was negatively associated with 569 570 antibody titer magnitude, suggesting that as time passes since full vaccination, the titer levels decrease. This time-dependent decay of antibodies was observed to have significant nonlinear components, particularly 571 following BV1 and BV2. 572

573

We also found that COVID-19 positive individuals had higher antibody levels following primary vaccination compared to COVID-19 negative individuals, and male participants had lower antibody titers compared to females. The type of vaccine received also affected antibody magnitude and durability; those who received the Pfizer BNT162b2 vaccine had lower titers than those who were given the Moderna mRNA-1273 vaccine. Differential antibody production between Moderna mRNA-1273 and Pfizer

28

BNT162b2 vaccines observed in our cohort are consistent with previous findings, which could be due to
varied anti-spike activity generated by each vaccine type (50, 51). We also observed that Moderna mRNA1273 half-dose recipients had higher post-booster Ab compared to those who received Pfizer BNT162b2
vaccination over time, but this effect was not observed following BV2. Interestingly, post-BV2 Ab were
not significantly affected by any predictive factors. This lack of predictors, including vaccine manufacturer,
suggest a more robust and homogeneous humoral immune response following BV2.

585

586 Conclusions

Overall, this study aimed to examine the effects of intrinsic and extrinsic health factors on Ab following 587 588 vaccination and through time using cross-sectional and longitudinal models. Differences in antibody titers 589 among the cohort were observed after primary vaccination for individuals with a history of drug use, prior 590 SARS-CoV-2 infection, hypertension, age, and biological sex. Differential titer production was also observed across females following BV1 and Hispanic participants following BV2. Linear-mixed effects 591 models used in this study aimed to control for random and fixed effects like population responses and 592 individual Ab variations over time and revealed trends in the decline of Ab over time following full 593 vaccination, as well as effects by COVID-19 vaccine manufacturer, prior SARS-CoV-2 infection, and 594 595 biological sex. Drug users and half-dose Moderna mRNA-1273 recipients had higher peak antibody titers 596 over time following the first booster, while no predictive factors significantly affected post-second booster 597 antibody responses. The absence of predictive factors for second booster immunogenicity suggests a more robust and consistent immune response after the second booster vaccine administration. 598

599

600

601 **Conflict of Interest**

It is made available under a CC-BY 4.0 International license .

29

602 Florian Krammer has been consulting for Curevac, Segirus and Merck and is currently consulting for Pfizer, Third Rock Ventures, Avimex and GSK. He is named on several patent regarding influenza virus and 603 604 SARS-CoV-2 virus vaccines, influenza virus therapeutics and SARS-CoV-2 serological tests. Some of 605 these technologies have been licensed to commercial entities and Dr. Krammer is receiving royalties from 606 these entities. Dr. Krammer is also an advisory board member of Castlevax, a spin-off company formed by 607 the Icahn School of Medicine at Mount Sinai to develop SARS-CoV-2 vaccines. The Krammer laboratory 608 has received funding for research projects from Pfizer, GSK and Dynavax and three of Dr. Krammer's mentees have recently joined Moderna. All other authors declare that they have no known competing 609 financial interests or personal relationships that could have appeared to influence the work reported in this 610 611 paper.

612

613 Funding

This work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza Vaccine
Innovation Centers (CIVIC) contract 75N93019C00051.

616

617 Acknowledgments

We thank Margaret Roach, Elizabeth Varghese, Maria Pallin, Celeste Sanchez, and Ailet Reyes for their technical contributions. We also thank Aria Nawab and Daniel Muniz for their assistance in sample collection, and Alexander Kizhner for his assistance with data management and in generating the early statistical analysis.

622

623

It is made available under a CC-BY 4.0 International license .

624 **References**

- 625 1. Wendisch D, Dietrich O, Mari T, von Stillfried S, Ibarra IL, Mittermaier M, et al. SARS-CoV-2
- 626 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021;184(26):6243-61.e27.
- 627 2. Jacobs JL, Haidar G, Mellors JW. COVID-19: Challenges of Viral Variants. Annu Rev Med.
- **628** 2023;74:31-53.
- Shishido AA, Barnes AH, Narayanan S, Chua JV. COVID-19 Vaccines-All You Want to Know.
 Semin Respir Crit Care Med. 2023;44(1):143-72.
- 4. Tsai SC, Lu CC, Bau DT, Chiu YJ, Yen YT, Hsu YM, et al. Approaches towards fighting the
- 632 COVID-19 pandemic (Review). Int J Mol Med. 2021;47(1):3-22.
- 633 5. Williams EC, Kizhner A, Stark VS, Nawab A, Muniz DD, Echeverri Tribin F, et al. Predictors for
- reactogenicity and humoral immunity to SARS-CoV-2 following infection and mRNA vaccination: A
- regularized, mixed-effects modelling approach. Frontiers in Immunology. 2023;14.
- 636 6. Moshkovits I, Shepshelovich D. Emergency Use Authorizations of COVID-19-Related Medical
- 637 Products. JAMA Intern Med. 2022;182(2):228-9.
- 638 7. Parums DV. Editorial: First Full Regulatory Approval of a COVID-19 Vaccine, the BNT162b2
- 639 Pfizer-BioNTech Vaccine, and the Real-World Implications for Public Health Policy. Med Sci Monit.
- 640 2021;27:e934625.
- 641 8. Forchette L, Sebastian W, Liu T. A Comprehensive Review of COVID-19 Virology, Vaccines,
 642 Variants, and Therapeutics. Curr Med Sci. 2021;41(6):1037-51.
- 643 9. Callegaro A, Borleri D, Farina C, Napolitano G, Valenti D, Rizzi M, et al. Antibody response to
- SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection. J Med
 Virol. 2021;93(7):4612-5.
- 646 10. Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, et al. Dynamics of
- 647 Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2
- 648 Infection. J Infect Dis. 2021;223(2):197-205.

649	11.	Hall V, Foulkes S, Insalata F, Kirwan P, Saei A, Atti A, et al. Protection against SARS-CoV-2
650	after C	ovid-19 Vaccination and Previous Infection. N Engl J Med. 2022;386(13):1207-20.
651	12.	Kelsen SG, Braverman AS, Aksoy MO, Hayman JA, Patel PS, Rajput C, et al. SARS-CoV-2
652	BNT16	2b2 vaccine-induced humoral response and reactogenicity in individuals with prior COVID-19
653	disease	. JCI Insight. 2022;7(4).
654	13.	Lozano-Ojalvo D, Camara C, Lopez-Granados E, Nozal P, Del Pino-Molina L, Bravo-Gallego
655	LY, et	al. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in
656	naive a	nd COVID-19 recovered individuals. Cell Rep. 2021;36(8):109570.
657	14.	Mungmunpuntipantip R, Wiwanitkit V. Antibody response to SARS-CoV-2 vaccination,
658	previou	as SARS-CoV-2 infection, and change to single-dose vaccination. J Med Virol. 2021;93(12):6474.
659	15.	Nagura-Ikeda M, Imai K, Kubota K, Noguchi S, Kitagawa Y, Matsuoka M, et al. Clinical
660	charact	eristics and antibody response to SARS-CoV-2 spike 1 protein using VITROS Anti-SARS-CoV-2
661	antibod	ly tests in COVID-19 patients in Japan. J Med Microbiol. 2021;70(4).
662	16.	Ontañón J, Blas J, de Cabo C, Santos C, Ruiz-Escribano E, García A, et al. Influence of past
663	infectio	on with SARS-CoV-2 on the response to the BNT162b2 mRNA vaccine in health care workers:
664	Kinetic	es and durability of the humoral immune response. EBioMedicine. 2021;73:103656.
665	17.	Pereson MJ, Amaya L, Neukam K, Baré P, Echegoyen N, Badano MN, et al. Heterologous gam-
666	COVII	D-vac (sputnik V)/mRNA-1273 (moderna) vaccination induces a stronger humoral response than
667	homolo	ogous sputnik V in a real-world data analysis. Clinical Microbiology and Infection.
668	2022;2	8(10):1382-8.
669	18.	Tsang JS, Dobaño C, VanDamme P, Moncunill G, Marchant A, Othman RB, et al. Improving
670	Vaccin	e-Induced Immunity: Can Baseline Predict Outcome? Trends Immunol. 2020;41(6):457-65.

- 19. Young KM, Gray CM, Bekker L-G. Is Obesity a Risk Factor for Vaccine Non-Responsiveness?
- 672 PLOS ONE. 2013;8(12):e82779.

- 673 20. Boroumand AB, Forouhi M, Karimi F, Moghadam AS, Naeini LG, Kokabian P, et al.
- 674 Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review. Frontiers
- 675 in Immunology. 2022;13.
- 676 21. Flanagan KL, van Crevel R, Curtis N, Shann F, Levy O, Network ftO. Heterologous
- 677 ("Nonspecific") and Sex-Differential Effects of Vaccines: Epidemiology, Clinical Trials, and Emerging
- 678 Immunologic Mechanisms. Clinical Infectious Diseases. 2013;57(2):283-9.
- 679 22. Posteraro B, Pastorino R, Di Giannantonio P, Ianuale C, Amore R, Ricciardi W, et al. The link
- between genetic variation and variability in vaccine responses: Systematic review and meta-analyses.
- 681 Vaccine. 2014;32(15):1661-9.
- 682 23. Grubeck-Loebenstein B, Della Bella S, Iorio AM, Michel J-P, Pawelec G, Solana R.
- 683 Immunosenescence and vaccine failure in the elderly. Aging Clinical and Experimental Research.
- **684** 2009;21(3):201-9.
- 685 24. Kumar R, Burns EA. Age-related decline in immunity: implications for vaccine responsiveness.
- 686 Expert Review of Vaccines. 2008;7(4):467-79.
- 687 25. Simon V, Kota V, Bloomquist RF, Hanley HB, Forgacs D, Pahwa S, et al. PARIS and SPARTA:
- Finding the Achilles' Heel of SARS-CoV-2. mSphere. 2022;7(3):e0017922.
- 689 26. HANC. Cross-Network PBMC Processing Standard Operating Procedure. 2018. p. 1-45.
- 690 27. Stadlbauer D, Amanat F, Chromikova V, Jiang K, Strohmeier S, Arunkumar GA, et al. SARS-
- 691 CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and
- Test Setup. Curr Protoc Microbiol. 2020;57(1):e100.
- 693 28. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M, et al. A
- 694 serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26(7):1033-6.
- 695 29. Sette A, Crotty S. Immunological memory to SARS-CoV-2 infection and COVID-19 vaccines.
- 696 Immunol Rev. 2022;310(1):27-46.
- 30. Baral S, Sherman SG, Millson P, Beyrer C. Vaccine immunogenicity in injecting drug users: a
- 698 systematic review. Lancet Infect Dis. 2007;7(10):667-74.

- 699 31. Friedman H, Newton C, Klein TW. Microbial infections, immunomodulation, and drugs of abuse.
- 700 Clin Microbiol Rev. 2003;16(2):209-19.
- 701 32. Friedman H, Pross S, Klein TW. Addictive drugs and their relationship with infectious deseases.
- FEMS Immunology & Medical Microbiology. 2006;47(3):330-42.
- 33. Re G-F, Jia J, Xu Y, Zhang Z, Xie Z-R, Kong D, et al. Dynamics and correlations in multiplex
- immune profiling reveal persistent immune inflammation in male drug users after withdrawal.
- 705 International Immunopharmacology. 2022;107:108696.
- 706 34. Mattson DL, Abais-Battad JM. T Cell Immunometabolism and Redox Signaling in Hypertension.
- 707 Curr Hypertens Rep. 2021;23(12):45.
- 708 35. Moshfegh CM, Case AJ. The Redox-Metabolic Couple of T Lymphocytes: Potential
- 709 Consequences for Hypertension. Antioxid Redox Signal. 2021;34(12):915-35.
- 710 36. Rai A, Narisawa M, Li P, Piao L, Li Y, Yang G, et al. Adaptive immune disorders in
- 711 hypertension and heart failure: focusing on T-cell subset activation and clinical implications. J Hypertens.
- 712 2020;38(10):1878-89.
- 713 37. Soegiarto G, Wulandari L, Purnomosari D, Dhia Fahmita K, Ikhwan Gautama H, Tri Hadmoko S,
- et al. Hypertension is associated with antibody response and breakthrough infection in health care
- vorkers following vaccination with inactivated SARS-CoV-2. Vaccine. 2022;40(30):4046-56.
- 716 38. Watanabe M, Balena A, Tuccinardi D, Tozzi R, Risi R, Masi D, et al. Central obesity, smoking
- habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA
- vaccine. Diabetes Metab Res Rev. 2022;38(1):e3465.
- 719 39. Pellini R, Venuti A, Pimpinelli F, Abril E, Blandino G, Campo F, et al. Initial observations on
- age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine.
- 721 EClinicalMedicine. 2021;36:100928.
- 40. Wolszczak-Biedrzycka B, Bieńkowska A, Dorf J. Assessment of Post-Vaccination Antibody
- 723 Response Eight Months after the Administration of BNT1622b2 Vaccine to Healthcare Workers with
- Particular Emphasis on the Impact of Previous COVID-19 Infection. Vaccines. 2021;9(12):1508.

- 41. Krammer F, Srivastava K, Alshammary H, Amoako AA, Awawda MH, Beach KF, et al.
- 726 Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. New
- 727 England Journal of Medicine. 2021;384(14):1372-4.
- 42. Bajaj V, Gadi N, Spihlman AP, Wu SC, Choi CH, Moulton VR. Aging, Immunity, and COVID-
- 19: How Age Influences the Host Immune Response to Coronavirus Infections? Frontiers in Physiology.
- 730 2021;11.
- 43. Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine
- responses. Journal of Allergy and Clinical Immunology. 2020;145(5):1309-21.
- 44. Song H, Price PW, Cerny J. Age-related changes in antibody repertoire: contribution from T
- cells. Immunological Reviews. 1997;160(1):55-62.
- 45. Weksler ME. Changes in the B-cell repertoire with age. Vaccine. 2000;18(16):1624-8.
- 46. Montecino-Rodriguez E, Berent-Maoz B, Dorshkind K. Causes, consequences, and reversal of
- 737 immune system aging. J Clin Invest. 2013;123(3):958-65.
- 738 47. Fink AL, Klein SL. The evolution of greater humoral immunity in females than males:
- implications for vaccine efficacy. Curr Opin Physiol. 2018;6:16-20.
- 48. Klein SL, Flanagan KL. Sex differences in immune responses. Nature Reviews Immunology.
 2016;16(10):626-38.
- 742 49. Ortona E, Pierdominici M, Rider V. Editorial: Sex Hormones and Gender Differences in Immune
 743 Responses. Front Immunol. 2019;10:1076.
- 50. Kelliher MT, Levy JJ, Nerenz RD, Poore B, Johnston AA, Rogers AR, et al. Comparison of
- 745 Symptoms and Antibody Response Following Administration of Moderna or Pfizer SARS-CoV-2
- 746 Vaccines. Arch Pathol Lab Med. 2022;146(6):677-85.
- 51. Keshavarz B, Richards NE, Workman LJ, Patel J, Muehling LM, Canderan G, et al. Trajectory of
- 748 IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and
- 749 Comparison With Natural Infection. Frontiers in Immunology. 2022;13.

It is made available under a CC-BY 4.0 International license .

750 Supporting information

751	S1 Table. Other Measured Extrinsic and Intrinsic Health Factors Among the Primary Vaccination
752	Sub-Cohort. ##: Levene's test found a statistically significant difference in the variances between
753	participants with and without hypertension (F (1,145) =8.15, p=0.005).
754	
755	S2 Table. Linear Mixed Effects Model (LMM) Evaluating the Relationship Between Post-Primary
756	Vaccination Antibody Titers and Time, COVID-19 Vaccine Manufacturer, Prior COVID-19
757	Infection Status, and Biological Sex.
758	
759	S3 Table. Other Measured Extrinsic and Intrinsic Health Factors Among the First Booster
760	Vaccination Sub-Cohort.
761	
762	S4 Table. Linear Mixed Effects Model (LMM) Evaluating the Relationship Between BV1 Antibody
763	Titers and Time, COVID-19 Vaccine Manufacturer, Prior COVID-19 Infection Status, and
764	Biological Sex.
765	
766	S5 Table. Other Measured Extrinsic and Intrinsic Health Factors Among the Second Booster
767	Vaccination Sub-Cohort.
768	
769	S6 Table. Linear Mixed Effects Model (LMM) Evaluating the Relationship Between BV2 Antibody
770	Titers and Time, COVID-19 Vaccine Manufacturer, Prior COVID-19 Infection Status, and
771	Biological Sex.











